Search results
The SEER database tracks 5-year relative survival rates for nasal cavity and paranasal sinus cancer in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by AJCC TNM stages (stages I to IV).
27 cze 2024 · Patients with adenocarcinoma and esthesioneuroblastoma had ideal overall survival prognosis, SCC (squamous cell carcinoma), SNMM (sinonasal mucosal melanoma), salivary carcinomas, SNUC (sinonasal undifferentiated carcinomas) poor, and SNEC (sinonasal neuroendocrine carcinoma) and NUT carcinoma (nuclear protein testis carcinoma) the worst prognosis.
6 cze 2022 · The five-year survival rate for localized nasal cavity and paranasal sinus cancer is about 86 percent. Regional — The cancer has spread from the sinus area to nearby lymph nodes or structures. The five-year survival rate for regional nasal cavity and paranasal sinus cancer is about 52 percent.
25 cze 2021 · Results. The 5-year outcomes were as follows: local control (LC), 80%; neck control, 96%; local-regional control, 78%; freedom from distant metastases, 71%; and disease-free survival, 62%; cause-specific survival, 64%; and overall survival, 59%.
28 kwi 2023 · Adenoid cystic carcinoma (87.5%) and SCC (65.3%) showed the best long-term overall survival. Regional involvement and regional recurrence are scarce. Because of rarity and heterogeneity, evidence on therapeutic management is sparse resulting in the lack of clinical guidelines.
1 lip 2024 · From diagnosis, across the span of 8 primary sites, first-year mortality rates q ranged from 14.3% (C30.0-nasal cavity) to 30.2% (C31.8-overlapping sinus) with corresponding excess death rates (EDR) of 118/1000/year and 279/1000/year.
The 5-year relative survival rate for localized disease is 85%. Regional means the cancer has spread outside the nasal cavity or paranasal sinus to nearby tissues or lymph nodes. It includes stage 3 cancers. The 5-year relative survival for regional disease is 50%.
